A Randomized, Parallel-Group, Multicenter Study to Examine the Safety, Tolerability, and Body Weight Effect of Subcutaneous Pramlintide Alone and in Combination With the Oral Antiobesity Agents Sibutramine or Phentermine in Overweight and Obese Subjects.

Trial Profile

A Randomized, Parallel-Group, Multicenter Study to Examine the Safety, Tolerability, and Body Weight Effect of Subcutaneous Pramlintide Alone and in Combination With the Oral Antiobesity Agents Sibutramine or Phentermine in Overweight and Obese Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2015

At a glance

  • Drugs Pramlintide (Primary) ; Phentermine; Sibutramine
  • Indications Obesity; Weight loss
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 21 Jan 2010 Results published in Obesity.
    • 07 Sep 2008 Results presented at the 44th Annual Meeting of the European Association for the Study of Diabetes.
    • 23 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top